SCHEMBL10046224

SCHEMBL10046224

CC(C)C(=O)[C@@H](N)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046227 1.00
SCHEMBL10460020 1.00
SCHEMBL4761845 0.79 GABRR1 (0.46)
SCHEMBL21122518 0.79 GABRR1 (0.46)
SCHEMBL12278736 0.79 GABRR1 (0.46)
SCHEMBL2625545 0.78
SCHEMBL4761841 0.78
SCHEMBL21345128 0.78
SCHEMBL12863852 0.78
SCHEMBL7555148 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds SYNEDGEN, INC. (US) 2023-10-17 US disclosed
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds SYNEDGEN, INC. (US) 2023-10-17 US disclosed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US disclosed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US disclosed
US-20230201248-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. 2023-06-29 US disclosed
US-20230201248-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. 2023-06-29 US disclosed
US-20230181623-A1 COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING SYNEDGEN, INC. 2023-06-15 US disclosed
US-20210386774-A1 METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK SYNEDGEN, INC. 2021-12-16 US disclosed
EP-2897622-B1 METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION SYNEDGEN INC (US) 2021-04-21 EP disclosed
US-10765616-B2 Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar SYNEDGEN, INC. (US) 2020-09-08 US disclosed
WO-2011028968-A1 ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN, INC. (US) 2011-03-10 WO disclosed
WO-2011028967-A1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN INC. (US) 2011-03-10 WO disclosed
US-20100137193-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH SYNEDGEN INC. (US) 2010-06-03 US disclosed
US-20100130443-A1 CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE SYNEDGEN INC. (US) 2010-05-27 US disclosed
WO-2010056896-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH SYNEDGEN, INC. (US) 2010-05-20 WO disclosed
WO-2010056927-A1 CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS SYNEDGEN, INC. (US) 2010-05-20 WO disclosed
US-20100056474-A1 Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds UNITED STATES GOVERNMENT 2010-03-04 US disclosed
WO-2010021930-A1 PREVENTION AND TREATMENT OF MRSA INFECTIONS WITH CHITOSAN-DERIVATIVES SYNEDGEN, INC. (US) 2010-02-25 WO disclosed
US-20090270457-A1 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-10-29 US disclosed
US-20070281904-A1 Chitosan-derivative compounds and methods of controlling microbial populations UNITED STATES GOVERNMENT 2007-12-06 US disclosed